Ron Strider
Well-Known Member
Growing biotech company strengthens sales team, prepares for product launch.
DENVER (October 11, 2017) – As Next Frontier Biosciences prepares to launch its Verra Wellness line of purified cannabinoid products in November, the Colorado-based biotech company has enhanced its experienced sales lineup with the addition of a new Regional Sales Manager, Colin Osborne.
In preparation for the product launch, Osborne plays a key role in generating a new customer base, forging and fostering strong relationships and educating clients on which products best suit their needs. In addition, he develops and implements an optimal sales strategy and product promotion while ensuring brand integrity.
Prior to joining Next Frontier Biosciences, Osborne worked in sales for nine years, notably serving as Sales Manager at Weaver Fundraising, LLC. He also served as Enterprise Software Sales Executive at BigMachines, Inc. and Executive Sales Representative at CBLPath, Inc. He later discovered a passion for the cannabis industry as Account Representative and Project Manager at ALl Packaging Company in Aurora, Colorado, and most recently in his role as Retail Associate at The Green Solution in Denver. A former Marine Officer, Osborne earned his bachelor’s degree from Gettysburg College and his master’s degree from Villanova University.
“Colin brings a strong and unique combination of leadership, sales and cannabis industry experience to Next Frontier Biosciences, making him well equipped to lead our regional sales team in introducing Verra Wellness to the market,” said Beth Dresser, Senior Director of Sales and Marketing at Next Frontier Biosciences. “We welcome his insights and know that our clients and staff will benefit from his guidance as we launch the brand in Colorado and establish ourselves as a global cannabis-infused products leader in other markets.”
For more information or to schedule an interview with Next Frontier Biosciences, please contact Shawna McGregor at 917-971-7852 or shawna@rosengrouppr.com.
About Next Frontier Biosciences:
Next Frontier Biosciences is a Colorado-based biotech company focused on developing and commercializing best-in-class purified cannabinoid products that are scientifically formulated for improved delivery. Comprised of an experienced group of biotechnology executives and research scientists, Next Frontier Biosciences is pioneering the development of purified cannabinoid products that provide accurate dosing, improved bioavailability and optimized cannabinoid profiles for fast acting and consistent results. Next Frontier Biosciences’ goal is to leverage its proprietary formulations and premium brand strategy to become a global leader in the market for next-generation cannabis infused products.
The company is led by a talented group of biotech executives and research scientists that help set it apart from the competition. Marc Graboyes, J.D., Next Frontier Biosciences’ co-founder and Chief Executive Officer, is responsible for leading the development and execution of the company’s long-term strategy as well as the day-to-day management of the company’s affairs. Mr. Graboyes has over two decades of experience working with emerging growth companies and the investors that support them, including eight years as Senior Vice President and General Counsel of Allos Therapeutics, Inc., a biotech company that he helped take public and sell for nearly $200 million. Prior to that, he was a corporate attorney with several large national law firms, including nearly five years with Cooley LLP. Mr. Graboyes is a seasoned business executive and attorney with deep experience in the areas of strategic planning, corporate finance, corporate development, technology transactions, and mergers and acquisitions, among other areas.
Dr. Paul Johnson, Ph.D., Next Frontier Biosciences’ co-founder and Chief Scientific Officer, has over four decades of experience in the pharmaceutical industry. He is an expert in intranasal drug development and delivery systems, and authored or invented over 100 patents and scientific publications. Dr. Johnson has experience in drug delivery and development, molecular diagnostics, cell biology, molecular biology and biochemistry/biophysics. In addition, he has led research and development activities for FDA approved drugs including Betaseron, the first-ever FDA approved drug to treat multiple sclerosis. He received a B.S. in Molecular Biology from the State University of New York, a Ph.D. in Biochemistry from the Roswell Park Cancer Institute, and conducted his postdoctoral training in biophysics and biology under an American Cancer Society fellowship at the California Institute of Technology.
Dr. Dorothy “Dot” Colagiovanni, Ph.D., Next Frontier Biosciences’ Vice President of Pharmaceutical Development, is responsible for the day-to-day management of the company’s research and development activities as well as supporting the commercialization of the company’s products. She has over two decades of pharmaceutical development experience with an emphasis on project management, pharmacology and toxicology. Prior to joining the company, Dr. Colagiovanni held scientific leadership roles with Nivalis Therapeutics and Replidyne, and she also held research positions with OSI Pharma, Gilead Sciences and Nexstar. Dr. Colagiovanni has a broad range of pharmaceutical development experience, starting with early drug discovery and clinical trials through regulatory approval and commercial launch. She completed her Ph.D. at University of Colorado Health Sciences Center in Molecular Toxicology and a postdoctoral fellowship at Amgen in hematotoxicology.
For more information, visit Age Verification. Follow us on Facebook, Twitter, Instagram and LinkedIn.
Welcome to the 420 Press Release Forum, created as a service to our readers solely for the dissemination of cannabis and hemp industry related press releases.
It is important for us to state that all press release information published on 420Magazine.com is ONLY based on what companies and individuals (i.e. third parties not associated with 420 Magazine) publish themselves and doesn’t involve any 420 Magazine’s editorial opinion or review. 420 Magazine takes no responsibility for and disclaims the information available in form of press releases across our website.
Some press releases may be confusing at first reading without additional explanation. In such case you should contact the press release author, either the company or the individual listed as the contact on the press release itself, with any additional questions regarding the information presented on their press release.
420 Magazine has zero tolerance towards objectionable and controversial PR materials published on its website. Any PR material found to be involved into a dispute, in one way or another, and is having one or more complaints received at 420 Magazine, against it supported with enough evidences that clearly indicate, in one way or another, it is harmful, even in a remote way, to the interest of 3rd parties is ground for taking the respective press release permanently down, without prior notice.
DENVER (October 11, 2017) – As Next Frontier Biosciences prepares to launch its Verra Wellness line of purified cannabinoid products in November, the Colorado-based biotech company has enhanced its experienced sales lineup with the addition of a new Regional Sales Manager, Colin Osborne.
In preparation for the product launch, Osborne plays a key role in generating a new customer base, forging and fostering strong relationships and educating clients on which products best suit their needs. In addition, he develops and implements an optimal sales strategy and product promotion while ensuring brand integrity.
Prior to joining Next Frontier Biosciences, Osborne worked in sales for nine years, notably serving as Sales Manager at Weaver Fundraising, LLC. He also served as Enterprise Software Sales Executive at BigMachines, Inc. and Executive Sales Representative at CBLPath, Inc. He later discovered a passion for the cannabis industry as Account Representative and Project Manager at ALl Packaging Company in Aurora, Colorado, and most recently in his role as Retail Associate at The Green Solution in Denver. A former Marine Officer, Osborne earned his bachelor’s degree from Gettysburg College and his master’s degree from Villanova University.
“Colin brings a strong and unique combination of leadership, sales and cannabis industry experience to Next Frontier Biosciences, making him well equipped to lead our regional sales team in introducing Verra Wellness to the market,” said Beth Dresser, Senior Director of Sales and Marketing at Next Frontier Biosciences. “We welcome his insights and know that our clients and staff will benefit from his guidance as we launch the brand in Colorado and establish ourselves as a global cannabis-infused products leader in other markets.”
For more information or to schedule an interview with Next Frontier Biosciences, please contact Shawna McGregor at 917-971-7852 or shawna@rosengrouppr.com.
About Next Frontier Biosciences:
Next Frontier Biosciences is a Colorado-based biotech company focused on developing and commercializing best-in-class purified cannabinoid products that are scientifically formulated for improved delivery. Comprised of an experienced group of biotechnology executives and research scientists, Next Frontier Biosciences is pioneering the development of purified cannabinoid products that provide accurate dosing, improved bioavailability and optimized cannabinoid profiles for fast acting and consistent results. Next Frontier Biosciences’ goal is to leverage its proprietary formulations and premium brand strategy to become a global leader in the market for next-generation cannabis infused products.
The company is led by a talented group of biotech executives and research scientists that help set it apart from the competition. Marc Graboyes, J.D., Next Frontier Biosciences’ co-founder and Chief Executive Officer, is responsible for leading the development and execution of the company’s long-term strategy as well as the day-to-day management of the company’s affairs. Mr. Graboyes has over two decades of experience working with emerging growth companies and the investors that support them, including eight years as Senior Vice President and General Counsel of Allos Therapeutics, Inc., a biotech company that he helped take public and sell for nearly $200 million. Prior to that, he was a corporate attorney with several large national law firms, including nearly five years with Cooley LLP. Mr. Graboyes is a seasoned business executive and attorney with deep experience in the areas of strategic planning, corporate finance, corporate development, technology transactions, and mergers and acquisitions, among other areas.
Dr. Paul Johnson, Ph.D., Next Frontier Biosciences’ co-founder and Chief Scientific Officer, has over four decades of experience in the pharmaceutical industry. He is an expert in intranasal drug development and delivery systems, and authored or invented over 100 patents and scientific publications. Dr. Johnson has experience in drug delivery and development, molecular diagnostics, cell biology, molecular biology and biochemistry/biophysics. In addition, he has led research and development activities for FDA approved drugs including Betaseron, the first-ever FDA approved drug to treat multiple sclerosis. He received a B.S. in Molecular Biology from the State University of New York, a Ph.D. in Biochemistry from the Roswell Park Cancer Institute, and conducted his postdoctoral training in biophysics and biology under an American Cancer Society fellowship at the California Institute of Technology.
Dr. Dorothy “Dot” Colagiovanni, Ph.D., Next Frontier Biosciences’ Vice President of Pharmaceutical Development, is responsible for the day-to-day management of the company’s research and development activities as well as supporting the commercialization of the company’s products. She has over two decades of pharmaceutical development experience with an emphasis on project management, pharmacology and toxicology. Prior to joining the company, Dr. Colagiovanni held scientific leadership roles with Nivalis Therapeutics and Replidyne, and she also held research positions with OSI Pharma, Gilead Sciences and Nexstar. Dr. Colagiovanni has a broad range of pharmaceutical development experience, starting with early drug discovery and clinical trials through regulatory approval and commercial launch. She completed her Ph.D. at University of Colorado Health Sciences Center in Molecular Toxicology and a postdoctoral fellowship at Amgen in hematotoxicology.
For more information, visit Age Verification. Follow us on Facebook, Twitter, Instagram and LinkedIn.
Welcome to the 420 Press Release Forum, created as a service to our readers solely for the dissemination of cannabis and hemp industry related press releases.
It is important for us to state that all press release information published on 420Magazine.com is ONLY based on what companies and individuals (i.e. third parties not associated with 420 Magazine) publish themselves and doesn’t involve any 420 Magazine’s editorial opinion or review. 420 Magazine takes no responsibility for and disclaims the information available in form of press releases across our website.
Some press releases may be confusing at first reading without additional explanation. In such case you should contact the press release author, either the company or the individual listed as the contact on the press release itself, with any additional questions regarding the information presented on their press release.
420 Magazine has zero tolerance towards objectionable and controversial PR materials published on its website. Any PR material found to be involved into a dispute, in one way or another, and is having one or more complaints received at 420 Magazine, against it supported with enough evidences that clearly indicate, in one way or another, it is harmful, even in a remote way, to the interest of 3rd parties is ground for taking the respective press release permanently down, without prior notice.